Luc Friboulet
0000-0002-1129-4978
Publication & Citation Trends
Publications
0 total
74TiP Unlock tarlatamab: A phase II, multicenter, open-label, study investigating tarlatamab in patients with metastatic/locally advanced small cell lung cancer and other poorly differentiated neuroendocrine carcinomas with integrated biomarker analyses
Cited by 0
Semantic Scholar
142P Single-cell RNA sequencing reveals EMT-activated fibroblast subset as a key mechanism of resistance to immune checkpoint blockers in NSCLC
Cited by 0
Semantic Scholar
140P Recurrent resistance mutations to lirafugratinib delineate treatment sequences for FGFR2-driven tumors
Cited by 0
Semantic Scholar
105P Paired liquid biopsies analysis reveals resistance mechanisms and prognostic factors in patients treated with KRASG12C inhibitors OA
Cited by 0
Semantic Scholar
1824P Sarcopenia in advanced non-small cell lung cancer (NSCLC): Clinical impact and its biological correlates
Cited by 0
Semantic Scholar
155TiP Exploring mechanisms of action and resistance to innovative therapeutic drugs: UNLOCK program
Cited by 0
Semantic Scholar
270 (PB258): Molecular and pharmacological profiling of a prostate cancer PDX panel and in vitro cellular counterparts to identify resistance mechanisms and new therapeutic options
Cited by 0
Semantic Scholar
A Model for Decoding Resistance in Precision Oncology: Acquired Resistance to FGFR inhibitors in Cholangiocarcinoma. OA
Cited by 24
Semantic Scholar
Research Topics
Cancer Genomics and Diagnostics
(222)
Lung Cancer Treatments and Mutations
(208)
Prostate Cancer Treatment and Research
(152)
Fibroblast Growth Factor Research
(124)
Bladder and Urothelial Cancer Treatments
(103)
Affiliations
Université Paris-Sud
Genomics Institute of the Novartis Research Foundation
Centre National de la Recherche Scientifique
Harvard University
Inserm